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Background: Atrial ﬁbrillation (AF) is one of the most common arrhythmias accounting for
signiﬁcant mortality and morbidity, especially in elderly. Though oral anticoagulation (OAC)
is an effective mode of prevention of stroke in patients of AF, bleeding complication remains
a major concern. Because of these issues, a signiﬁcant proportion of patients either does not
receive or receive suboptimal doses of OAC.
Methods: In such patients, percutaneous left atrial appendage (LAA) closure remains an
interesting option. Experience and literature of this procedure from India have been sparse.
We report the ﬁrst single center experience, from India, of percutaneous LAA closure with
Amplatzer Cardiac Plug in 10 patients of non-valvular AF. These patients had contraindica-
tions for OAC or had high risk of bleeding or labile international normalized ratio (INR) on
therapy.
Results: We successfully deployed the devices in all of the cases with no major complications
perioperatively and on short-term follow-up. We also report a comprehensive review on the
technique of percutaneous LAA closure using Amplatzer Cardiac Plug, including some novel
modiﬁcation with our experience of doing percutaneous mitral balloon valvuloplasty.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
Available online at www.sciencedirect.com
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Atrial ﬁbrillation (AF) is one of the most common cardiac
arrhythmias, which affects around 3–5% of population
between 65 and 75 years of age. The prevalence increases to
>8% in patients above the age of 80 years.1 Ischemic stroke is§ Read the Editorial to this manuscript: Percutaneous left atrial app
new era.
* Corresponding author.
http://dx.doi.org/10.1016/j.ihj.2015.07.011
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierthe most disabling morbidity due to AF especially in elderly.
Stroke risk in patients with non-valvular AF (NVAF) is around
3–5% per year. Overall AF accounts up to 30% of stroke in
patients over 80 years of age.2
Oral anticoagulation (OAC) is the standard treatment for
stroke prevention in patients with NVAF with CHA2DS2-VASc
stroke risk score ≥ 1.3 OAC is effective in stroke prevention, butendage closure for stroke prevention in India: The beginning of a
 B.V. All rights reserved.
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patients from taking this therapy.4,5 Percutaneous left atrial
appendage (LAA) occlusion is a new and emerging therapy,
which provides an alternative to OAC in patients with high
stroke risk and contraindication to OAC. The rationale behind
LAA occlusion using a device is that >90% of thrombi in
patients with NVAF are located in LAA, whereas in patients
with valvular AF, only 60% of thrombi are located in the LAA.6
Currently, LAA closure has been given a Class IIb recommen-
dation in AHA/ESC 2014 guidelines. There are number of
devices available at present, WATCHMAN device and the
AMPLATZER CARDIAC PLUG (ACP) to name a few. The
experience of this procedure is limited in India, and there
are no published data from our country regarding this evolving
therapy. Thus, we intend to share our experience of LAA
closure from a single center in India with relevant review of
literature through this report.
2. Case selection
Between December 2014 to February 2015, 10 consecutive
patients of NVAF who were currently on OAC (warfarin or
novel anticoagulants) but had high risk of bleeding or labile
international normalized ratio (INR) on therapy or discon-
tinued treatment with OAC due to potential risk of bleedingTable 1 – Patients baseline profile, TEE and angiogrpahic meas
Age
(years)/
sex
Risk factors
apart from
age
CHA2DS2-VASc
risk score
Bleeding r
(HAS-BLE
score)
Case 1 77/male Hypertension 3 3 (high risk
bleeding)
Case 2 67/female Hypertension 3 3 (high risk
bleeding)
Case 3 68/male Hypertension 2 3 (high risk
bleeding)
Case 4 69/female Diabetes,
hypertension
4 3 (high risk
bleeding)
Case 5 58/female Hypertension 2 3 (high risk
bleeding)
Case 6 73/female Hypertension 3 3 (high risk
bleeding)
Case 7 67/female Hypertension 3 3 (high risk
bleeding)
Case 8 71/male Congestive
cardiac failure
2 3 (high risk
bleeding)
Case 9 68/female Hypertension 3 3 (high risk
bleeding)
Case 10 75/female Hypertension 4 3 (high risk
bleeding)
CHA2DS2-VASc – stoke risk scoring system includes Congestive cardia
Diabetes (1 point); previous Stroke or transient ischemic attacks (2 poin
point); HAS-BLED-BLEEDING RISK SCORE includes Hypertension (uncontr
and/or liver function (1 point), previous Stroke (1 point), Bleeding history
concomitant Drugs and/or alcohol excess. TEE – transesophageal echocar
RAO – right anterior oblique.were enrolled for the procedure. The baseline characteristics
and risk factors of the patients are shown in Table 1. All the
patients had CHA2DS2-VASc risk score of >1. Their bleeding
risk was high as calculated by the HAS-BLED score, which was
3 in all the cases. Four of the patients had labile INR on
treatment. We enrolled these patients for percutaneous LAA
closure using Amplatzer Cardiac Plug (ACP 1).
3. Procedure and device implantation
3.1. Imaging during the procedure
A pre-procedure transthoracic echocardiography (TTE) was
done in all the cases to assess the left ventricular function and
any contraindication to device closure. Ideally a pre-procedure
transesophageal echocardiography (TEE) should be done to
assess the LAA anatomy and feasibility for device occlusion.
TEE was also done during the procedure to assess LAA
anatomy, size of the ostium, and size of landing zone for
the device lobe, which are needed to determine the size of the
device. Ostium of LAA is measured at the level of left
circumﬂex artery (LCX) and the left upper pulmonary vein
(LUPV). The measurement of landing zone is taken 10 mm
inside the ostium perpendicular to neck of LAA (Fig. 1). The size
of the landing zone determines the size of the lobe of ACP to beurements of LAA and size of the device selected.
isk
D
LAA
ostium
on TEE
(short axis)
(mm)
Size of
landing
zone on tee
(short axis)
(mm)
Angiographic
measurements
of landing
zone in RAO
cranial view
(mm)
Size of the
ACP device
selected for
LAA closure
(mm)
 of 22.7 19 20 22
 of 20.4 16.8 18 22
 of 31.6 24.6 24 30
 of 21.7 17.9 20 24
 of 22 17.6 18 22
 of 22.8 20 17 24
 of 25.6 22.8 23 26
 of 33.10 24.18 24.18 28
 of 23.6 18.25 15.55 22
 of 24.1 19.3 18 22
c failure (1 point), Hypertension (1 point), Age ≥ 75 years (2 point);
t), Vascular disease (1 point), Age 65–74 (1 point) and female Sex (1
olled systolic blood pressure >160 mm Hg) (1 point), Abnormal renal
 or predisposition (1 point), Labile INR (1 point), Elderly (1 point), and
diography; LAA – left atrial appendage; ACP – Amplatzer Cardiac Plug;
Fig. 1 – Transesophageal echocardiography showing the LAA
and the measurements to be taken (A – ostium of LAA; B –
measurement of the landing zone which is 10 mm inside the
ostium perpendicular to neck of LAA; C – LUPV; D – LCX). Fig. 3 – Angiography in right anterior oblique view opacifying
the LAA and the measurements to be taken (A – ostium of
the LAA; B – distance between the ostium and the landing
zone for the device in LAA (10 mm); C – measurement of the
landing zone for the lobe of the device).
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Table 1.
3.2. Access and transseptal puncture technique
All the procedures were done under general anesthesia after
taking informed consent. Right femoral vein was cannulated
using Seldinger technique. Transseptal puncture was done
with the help of Brockenbrough septal puncture needle, under
TEE guidance. The site of the transseptal puncture differs from
that of the balloon mitral valvotomy (BMV), in that it is done
posterior and inferior to fossa ovalis in order to align the
delivery sheath to LAA (Fig. 2). The Mullen's sheath is then
passed over the puncture needle in the left atrium (LA). 6-Fr
sizing pigtail catheter is taken inside the Mullen's sheath into
LA to facilitate for angiography of LAA.Fig. 2 – Transesophageal echocardiography-guided
transseptal puncture which is posterior and inferior to the
fossa ovalis (A – tenting of the atrial septum;
B – brockenbrough needle).3.3. Angiography
The Mullen's sheath and the pigtail are then guided into the
LAA body by anticlockwise torque on the pigtail. Once the
pigtail is inside the body of LAA, angiographic views in right
anterior oblique (RAO) 208 and cranial 208 were taken by
contrast injections through the Mullen's sheath. LAA ostium
measurements and landing zone measurements were done
(Fig. 3). If required, additional views such as RAO caudal were
taken to delineate the LAA anatomy clearly. After taking
angiographic measurements in different views and comparing
it with TEE measurements, appropriate size of the device was
chosen. The device selected is based on the lobe size of ACP
and measurement of the landing zone. The lobe size should be
3–6 mm more than the measurements of the landing zone. The
respective sizes of the devices in each of the cases are shown in
Table 1.
3.4. Technique of device implantation
After angiography, Mullen's sheath was exchanged with an
exchange length 0.03500 super stiff wire, which was placed in
the LUPV. Then, an Inoue dilator was used to dilate the skin
and soft tissues and the interatrial septum. This step been
seldom described in any of the reviews from other countries
and is a novel modiﬁcation from our experience, from doing
percutaneous BMV. This step of dilating the soft tissue and
interatrial septum allows easy passage of the delivery sheath
for device deployment. The appropriate-sized delivery sheath
was then introduced over the super stiff wire up to the LUPV.
The device was then loaded into delivery cable and introduced
inside the delivery sheath up to the end of the sheath. The
delivery sheath, which was resting in the LUPV, was then
pulled back slightly, which makes it to face the LAA ostium.
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forms a ball shape. After which, the whole system is pushed
inside the body of LAA, and continuous monitoring with the
help of TEE was done. Once on TEE, it is conﬁrmed that two
third of the lobe is beyond the LCX artery, an anticlockwise
torque to the delivery sheath was given and device was further
pushed out till the lobe of ACP is deployed. This anticlockwise
torque helps to align the ACP perpendicular to neck of the LAA.
The lobe should attain a shape of a tyre before further
deployment of the device. Once satisfactory shape and
location of the lobe are conﬁrmed on TEE, the disk of the
device was deployed by pulling back the delivery sheath and
maintaining a traction on the delivery cable.
3.5. Checklist before ﬁnal release of the device (Fig. 4)
1. Tyre shape of the lobe.
2. Good separation between the lobe and disk.
3. Disk is concave in shape.
4. Disk should seal the ostium of the LAA completely. This is
conﬁrmed by angiography via injection of contrast through
the delivery sheath. It can also be conﬁrmed by color
Doppler on TEE. Jet width up to 3 mm on TEE is accepted
across the device.
5. Two third of the lobe should be inside the LCX artery on TEE.
6. ACP should parallel the LAA neck.
After conﬁrming all these points, the device is ﬁnally
released by rotating the delivery cable in anticlockwise
manner till the device was ﬁnally released. The delivery cable
and sheath were taken out and local hemostasis was achieved
by local compression at the puncture site.
In our case series, all the cases were performed by 2
operators. We did not have any screen failures. In 80% of cases
(8 out of 10 cases), device was deployed in the ﬁrst attempt, but
in 2 cases, we had to retrieve and reposition the device. In 10%
of cases (1 out of 10 cases), device was deployed in secondFig. 4 – Fluoroscope image showing the final deployed
device.attempt, and in 10% of cases (1 out of 10 cases), device was
deployed in third attempt.
3.6. Post-procedure treatment and follow-up
Post-procedure, all patients were put on OAC with warfarin for
45 days along with single antiplatelet agent. Then, OAC was
stopped and dual antiplatelet continued for six months, after
which single antiplatelet will be continued indeﬁnitely if there
is no contraindication. Post-procedure TEE was done before
discharge to look for early device embolization. Repeat TEE,
done at six weeks, showed device in situ in all cases with no
major complications. At 3rd month (8 cases) and 6th month (2
cases) follow-ups, there were no major complications and
closure rates were 100% in all cases.
3.7. Possible complications
1. Cardiac perforation and pericardial effusion due to trans-
septal puncture or due to device itself. Cardiac perforation
up to 7 days is reported due to device.
2. Pericardial effusion and cardiac tamponade.
3. Device embolization (early and late).
4. Device thrombosis.
5. Stroke/TIA – thromboembolism, air embolism.
6. Vascular complications – hematoma, bleeding.
No such major or minor complications were noted during
the procedure in any of our cases.
4. Discussion
First case of percutaneous LAA closure was done in 2002, after
that a number of studies have been done, which shows that this
strategy is safe and efﬁcacious in indicated patients of NVAF.
PLAATO was the ﬁrst approved device for LAA closure, which
was evaluated by 2 multicentric prospective study with positive
results on 5-year follow-up.7,8 The recently concluded random-
ised controlled trials like PROTECT AF and PREVAIL study, which
used the WATCHMAN device, showed LAA closure to be non-
inferior to OAC and had less bleeding risk when compared to
OAC. These studies also showed percutaneous LAA closure to be
superior to OAC in terms of stroke prevention and had a larger
'net clinical beneﬁt' than OAC in patients with higher stroke
risk.9,10 The device which was used in our study was Amplatzer
Cardiac Plug (ACP) (St. Jude). The ACP is a self-expandable nitinol
device with a polyester patch within, formed by three parts: a
cylindrical lobe with a ﬁxed length of 6.5 mm, to which diameter
(16–30 mm, stepwise by 2 mm) the prosthesis size refers; an
occlusive disk, 4 mm larger than the 16–22 mm prosthesis, and
6 mm larger than the 24–30 mm devices; and a ﬂexible central
connector pine. There are six pairs of barbs attached to the lobe
and directed to the disk, all identiﬁed by radiopaque marks, to
enhance the retention of the lobe in LAA. The occlusive disk
permits the complete closure of the LAA oriﬁce by a paciﬁer
principle, and enables this device to be useful in any anatomical
variants of LAA (Fig. 5).
Recent AHA/ESC guidelines have given a class IIb recom-
mendation for percutaneous LAA closure in patients with
Fig. 5 – The Amplatzer Cardiac Plug and the ‘‘pacifier principle’’.
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contraindication to long-term OAC therapy. Other indications
are high risk of stroke with relative contraindications to OAC
therapy and patients with labile INR.
While there is considerable experience and exposure for
percutaneous LAA closure outside India, there are no reported
cases from India till now. Thus, through this report, we intend
to share our experience of percutaneous LAA closure with ACP
in 10 successful cases and to report a comprehensive review on
the technique of percutaneous LAA closure using ACP,
including some novel modiﬁcation with our experience of
doing BMV. So far, we had no complications during or after the
procedure, and all cases are doing well on short-term follow-
up. It is important to understand that it is still an emerging and
evolving therapy, and safety is of utmost importance.
Moreover, imaging with TEE during the procedure is an
integral part of performing successful percutaneous LAA
closures. The anatomy of LAA is highly variable and can offer
many procedural difﬁculties and challenges. Finally, we need
further studies and long-term follow-up to reﬁne patient
selection, to select an ideal post-procedural antithrombotic
therapy, and to document long-term efﬁcacy of percutaneous
LAA closure.
Our short-term experience with LAA closure with ACP
suggests that it is a safe and feasible procedure with
encouraging short-term outcomes. It may provide alternative
strategy to OAC therapy in patients with AF-induced high
stroke risk and intolerance for OAC. Further, large-scaled trials
are needed to conﬁrm the efﬁcacy of this procedure.
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